These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 22872694)

  • 21. Opportunities for vaccine research in Europe.
    Gancberg D; Hoeveler A; Martini A; Draghia-Akli R
    Hum Vaccin Immunother; 2015; 11(8):1917-20. PubMed ID: 26090718
    [No Abstract]   [Full Text] [Related]  

  • 22. The role of innovation in drug development.
    Drews J; Ryser S
    Nat Biotechnol; 1997 Dec; 15(13):1318-9. PubMed ID: 9415870
    [No Abstract]   [Full Text] [Related]  

  • 23. The economics of drug development: a grim reality and a role for clinical pharmacology.
    Honig P; Lalonde R
    Clin Pharmacol Ther; 2010 Mar; 87(3):247-51. PubMed ID: 20160740
    [No Abstract]   [Full Text] [Related]  

  • 24. The state of innovation in drug development.
    Kola I
    Clin Pharmacol Ther; 2008 Feb; 83(2):227-30. PubMed ID: 18202690
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Managing Innovation to Maximize Value Along the Discovery-Translation-Application Continuum.
    Waldman SA; Terzic A
    Clin Pharmacol Ther; 2017 Jan; 101(1):8-12. PubMed ID: 27869291
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Defining "innovativeness" in drug development: a systematic review.
    Kesselheim AS; Wang B; Avorn J
    Clin Pharmacol Ther; 2013 Sep; 94(3):336-48. PubMed ID: 23722626
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Can open-source drug R&D repower pharmaceutical innovation?
    Munos B
    Clin Pharmacol Ther; 2010 May; 87(5):534-6. PubMed ID: 20407458
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Importance of Economic Trade-offs in Cancer Drug Pricing.
    Fonseca R; Peneva D; Clancy Z; Abouzaid S; Jena AB
    Mayo Clin Proc; 2018 Aug; 93(8):976-979. PubMed ID: 29945732
    [No Abstract]   [Full Text] [Related]  

  • 29. The economics of resistant pathogens and antibiotic innovation.
    McKellar MR; Chernew ME; Fendrick AM
    Am J Manag Care; 2014 Mar; 20(3):193-7. PubMed ID: 24884749
    [No Abstract]   [Full Text] [Related]  

  • 30. ASCPT Task Force for advancing pharmacometrics and integration into drug development.
    Goldberger MJ; Singh N; Allerheiligen S; Gobburu JV; Lalonde R; Smith B; Ryder S; Yozviak A
    Clin Pharmacol Ther; 2010 Aug; 88(2):158-61. PubMed ID: 20648032
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug development: a complicated path.
    Humphries C
    Nature; 2014 Nov; 515(7526):S4-5. PubMed ID: 25390140
    [No Abstract]   [Full Text] [Related]  

  • 32. Economic models in type 2 diabetes.
    Yi Y; Philips Z; Bergman G; Burslem K
    Curr Med Res Opin; 2010 Sep; 26(9):2105-18. PubMed ID: 20642392
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How should we support pharmaceutical innovation?
    Grootendorst P
    Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):313-20. PubMed ID: 19670991
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Global drug discovery: Europe is ahead.
    Light DW
    Health Aff (Millwood); 2009; 28(5):w969-77. PubMed ID: 19706628
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patients often go without effective new treatments, especially in rare disease patient populations where profit potential is limited.
    Bloom BE
    Contemp Clin Trials; 2011 Mar; 32(2):151-2. PubMed ID: 21238613
    [No Abstract]   [Full Text] [Related]  

  • 36. Big pharma shows signs of renewed interest in RNAi drugs.
    Zeliadt N
    Nat Med; 2014 Feb; 20(2):109. PubMed ID: 24504395
    [No Abstract]   [Full Text] [Related]  

  • 37. Of silver bullets and red herrings: invited commentary to Fisk et al.
    Razum O; Schaaber J; Nayar KR
    Trop Med Int Health; 2011 Jun; 16(6):669-71. PubMed ID: 21501348
    [No Abstract]   [Full Text] [Related]  

  • 38. A bitter pill.
    Nat Chem; 2010 May; 2(5):337. PubMed ID: 20414223
    [No Abstract]   [Full Text] [Related]  

  • 39. Novel trends in high-throughput screening.
    Mayr LM; Bojanic D
    Curr Opin Pharmacol; 2009 Oct; 9(5):580-8. PubMed ID: 19775937
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [A model for structured introduction of new drugs. The aim is to offer all patients appropriate treatment].
    Gustafsson LL; Wettermark B; Kalin M; Korkmaz S; Persson ME; Almkvist H; Hjemdahl P; Julander M; Kristianson K; Ringertz B; Bergen-Dahl GT; Wilking N
    Lakartidningen; 2008 Oct 15-21; 105(42):2917-22. PubMed ID: 19025148
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.